English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Procalcitonin (PCT) is a 13-kDa peptide and a precursor of calcitonin. In a healthy population, PCT concentrations are negligible (1). In systemic bacterial and fungal infections, plasma concentrations are raised, whereas concentrations remain fairly low in infections of viral or nonspecific cause (2). Recent studies have demonstrated the potential of PCT as a parameter to guide antibiotic therapy in different groups of patients, i.e., patients with chronic obstructive pulmonary disease experiencing respiratory tract infections (3)(4). The most frequently used medical decision points at which the use of antibiotic therapy is considered are 0.25 μg/L and 0.50 μg/L, depending on the patient population (3)(4).The first PCT assays were based on manual immunochemistry methods (Brahms PCT LIA). These assays have been replaced by fully automated immunochemistry methods (Brahms Kryptor, Brahms LIAISON, Olympus SphereLight 180). Recently, the PCT assay has been modified for use on a consolidated routine immunochemistry analyzer family, the Roche Elecsys, cobas, and the Roche Modular E170 systems. We evaluated the analytical performance of this new assay by following the EP10 protocol, a …

Comparison of a New Procalcitonin Assay from Roche with the Established Method on the Brahms Kryptor